Search
Shanghai Biomedical M&A Fund Strategically Acquires Kanghua Biological
2025-07-21 /
Read about 0 minute
Author：小编
The M&A fund strategically intends to acquire Kanghua Biological via a negotiated agreement. Leveraging its substantial resources and capital, the fund will bolster Kanghua Biological's production and sales of mature products, while exploring synergies within the vaccine industry between Shanghai and Chengdu. The ultimate goal is to expedite the development of a diversified vaccine portfolio, fostering an ecosystem that harmoniously integrates maturity and innovation.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
